Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal hemodynamic effects of RLX030 in chronic heart failure
2011-001588-37Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic heart failure (CHF) comparing RLX030 30 μg/kg/day with Placebo (2 arms). Primary endpoint: Renal blood flow. Started Sep 2011; status: completed.
02
Drugs
serelaxin
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on 2011-001588-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001588-37.